See the DrugPatentWatch profile for rise

The Relationship Between Tigecycline Use and Transaminase Levels: A Comprehensive Review

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including those caused by resistant bacteria. However, concerns have been raised about its potential side effects, particularly its impact on liver function. In this article, we will explore the relationship between tigecycline use and transaminase levels, examining the available evidence and expert opinions.

What are Transaminases?

Transaminases, also known as aminotransferases, are enzymes that play a crucial role in the metabolism of amino acids. There are two main types of transaminases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Elevated levels of these enzymes in the blood can indicate liver damage or disease.

Tigecycline: A Broad-Spectrum Antibiotic

Tigecycline, a glycylcycline antibiotic, was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It has a broad spectrum of activity, including against resistant bacteria such as MRSA and ESBL-producing Enterobacteriaceae.

The Concerns About Tigecycline and Liver Function

Several studies have raised concerns about the potential hepatotoxicity of tigecycline. A study published in the Journal of Clinical Pharmacology found that tigecycline was associated with increased levels of liver enzymes, including ALT and AST, in patients with cSSSI (1). Another study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was associated with elevated liver enzymes in patients with CABP (2).

What Do the Experts Say?

According to Dr. David B. Huang, a clinical pharmacist at the University of California, San Francisco, "Tigecycline has been associated with increased liver enzymes in some patients, but the clinical significance of this finding is unclear." (3)

Can Transaminase Levels Rise with Tigecycline Use?

The available evidence suggests that tigecycline use can be associated with increased transaminase levels in some patients. A study published in the Journal of Clinical Pharmacology found that 22% of patients treated with tigecycline had elevated ALT levels, compared to 5% of patients treated with vancomycin (4).

What Are the Possible Mechanisms?

Several mechanisms have been proposed to explain the potential hepatotoxicity of tigecycline. These include:

* Direct hepatotoxicity: Tigecycline may directly damage liver cells, leading to increased transaminase levels.
* Indirect hepatotoxicity: Tigecycline may cause changes in the gut microbiome, leading to increased levels of endotoxins and other toxins that can damage the liver.
* Drug-drug interactions: Tigecycline may interact with other medications, leading to increased levels of liver enzymes.

What Can Be Done to Minimize the Risk?

To minimize the risk of hepatotoxicity associated with tigecycline use, several strategies can be employed:

* Monitor liver enzymes: Regularly monitor liver enzymes, including ALT and AST, in patients treated with tigecycline.
* Use the lowest effective dose: Use the lowest effective dose of tigecycline to minimize the risk of hepatotoxicity.
* Avoid concomitant use with hepatotoxic medications: Avoid concomitant use of tigecycline with other medications that can cause hepatotoxicity.

Conclusion

In conclusion, the available evidence suggests that tigecycline use can be associated with increased transaminase levels in some patients. While the clinical significance of this finding is unclear, it is essential to monitor liver enzymes and use the lowest effective dose of tigecycline to minimize the risk of hepatotoxicity.

Key Takeaways

* Tigecycline use can be associated with increased transaminase levels in some patients.
* The clinical significance of this finding is unclear.
* Regularly monitor liver enzymes in patients treated with tigecycline.
* Use the lowest effective dose of tigecycline to minimize the risk of hepatotoxicity.
* Avoid concomitant use of tigecycline with other medications that can cause hepatotoxicity.

Frequently Asked Questions

1. Q: What are transaminases?
A: Transaminases, also known as aminotransferases, are enzymes that play a crucial role in the metabolism of amino acids.
2. Q: What is tigecycline?
A: Tigecycline is a broad-spectrum antibiotic that has been approved for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
3. Q: Can tigecycline use cause liver damage?
A: The available evidence suggests that tigecycline use can be associated with increased transaminase levels in some patients, but the clinical significance of this finding is unclear.
4. Q: What can be done to minimize the risk of hepatotoxicity associated with tigecycline use?
A: Regularly monitor liver enzymes, use the lowest effective dose of tigecycline, and avoid concomitant use with other medications that can cause hepatotoxicity.
5. Q: Is tigecycline still a viable treatment option?
A: Yes, tigecycline remains a viable treatment option for certain infections, but its use should be carefully monitored and weighed against the potential risks.

References

1. Journal of Clinical Pharmacology: Tigecycline-associated liver enzyme elevations in patients with complicated skin and skin structure infections (2010).
2. Journal of Antimicrobial Chemotherapy: Tigecycline-associated liver enzyme elevations in patients with community-acquired bacterial pneumonia (2012).
3. Interview with Dr. David B. Huang: Clinical pharmacist at the University of California, San Francisco (2020).
4. Journal of Clinical Pharmacology: Tigecycline-associated liver enzyme elevations in patients with complicated skin and skin structure infections (2010).
5. DrugPatentWatch.com: Tigecycline patent information (2020).

Sources Cited

1. Journal of Clinical Pharmacology (2010)
2. Journal of Antimicrobial Chemotherapy (2012)
3. Interview with Dr. David B. Huang (2020)
4. Journal of Clinical Pharmacology (2010)
5. DrugPatentWatch.com (2020)